

Amendments to the Claims

This listing of the claims will replace all prior versions and listings of the claims.

Listing of Claims:

1. (Original) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
 - (f) a polynucleotide which is a variant of SEQ ID NO:X;
 - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
 - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
 - (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2-10. (Canceled)

11. (Original) An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. (Canceled)

13. (Original) An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14-16. (Canceled)

17. (Original) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

18. (Original) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.

19. (Original) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

20. (Original) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

21. (Original) A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

22-23. (Canceled)

24. (Original) The product produced by the method of claim 20.
25. (New) An isolated protein comprising an amino acid sequence selected from the group consisting of:
- (a) amino acid residues 24 to 522 of SEQ ID NO:222;
 - (b) amino acid residues 2 to 522 of SEQ ID NO:222; and
 - (c) amino acid residues 1 to 522 of SEQ ID NO:222;
26. (New) The isolated protein of claim 25, which comprises amino acid sequence (a).
27. (New) The isolated protein of claim 25 which comprises amino acid sequence (b).
28. (New) The isolated protein of claim 25 which comprises amino acid sequence (c).
29. (New) The isolated protein of claim 25 which comprises amino acid sequence (f).
30. (New) The isolated protein of claim 25 which further comprises a heterologous polypeptide sequence.
31. (New) The isolated protein of claim 30 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.
32. (New) The isolated protein of claim 25 wherein said isolated protein is glycosylated.
33. (New) The protein of claim 25 wherein said isolated protein is fused to polyethylene glycol.

34. (New) A composition comprising the protein of claim 25 and a pharmaceutically acceptable carrier.

35. (New) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 25 by a cell; and
- (b) recovering said protein.

36. (New) An isolated protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of the mature form of the polypeptide encoded by the HOGCK20 cDNA contained in ATCC Deposit No. 209853;

(b) the amino acid sequence of the complete polypeptide encoded by the HOGCK20 cDNA contained in ATCC Deposit No. 209853, excepting the N-terminal methionine; and

(c) the amino acid sequence of the complete polypeptide encoded by the HOGCK20 cDNA contained in ATCC Deposit No. 209853.

37. (New) The isolated protein of claim 36, wherein said amino acid sequence is (a).

38. (New) The isolated protein of claim 36, wherein said amino acid sequence is (b).

39. (New) The isolated protein of claim 36, wherein said amino acid sequence is (c).

40. (New) The isolated protein of claim 36 which further comprises a heterologous polypeptide sequence.

41. (New) The isolated protein of claim 40 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.

42. (New) The isolated protein of claim 36 wherein said isolated protein is glycosylated.

43. (New) The isolated protein of claim 36 wherein said isolated protein is fused to polyethylene glycol.

44. (New) A composition comprising the protein of claim 36 and a pharmaceutically acceptable carrier.

45. (New) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 36 by a cell; and
(b) recovering said protein.